banter and General Discussion, page-8331

Like I stated in Post #:69920461 back in Sept 2023 when I sold parcels at 47 cents .... there won't be a quick fix to this Remestemcel-L / FDA situation ... those that were getting their hopes up about the Type A meeting back then and the "supposed" 45 day timeline, ease of solution etc etc have once again been let down through further delays and yet another dilutionary capital raise - I don't see a solution prior to 31 March if we are even that lucky that we get it by then as it could be even longer ?


..... and as for the rhetoric this morning that no trials will start until Remestemcel is approved - I just cannot accept that as a logical argument ? It would mean that Mesoblast would 'basically' be a white elephant chewing through $ to keep the lights while they wait at the mercy of the FDA decision on Remestemcel-L ? Rexlemestrocel-L has RMAT's for both CHF and CLBP indications so why put them on the back burner and undertake no trials in the interim all in hope that the FDA approve Remestemcel-L ..... eventually ?










.... and meanwhile stem cell treatments in the USA are good enough for sitting congressmen - just not Mesoblast's by the looks ?



https://www.washingtonpost.com/politics/2024/01/05/steve-scalise-house-republicans/

Scalise temporarily leaves Washington for stem cell treatment